SE383522B - Forfarande for framstellning av anti-inflammatoriskt verksamma 17-karboxylat av steroider tillhorande androstan-serien. - Google Patents

Forfarande for framstellning av anti-inflammatoriskt verksamma 17-karboxylat av steroider tillhorande androstan-serien.

Info

Publication number
SE383522B
SE383522B SE7200662A SE66272A SE383522B SE 383522 B SE383522 B SE 383522B SE 7200662 A SE7200662 A SE 7200662A SE 66272 A SE66272 A SE 66272A SE 383522 B SE383522 B SE 383522B
Authority
SE
Sweden
Prior art keywords
carboxylate
inflammatory
efficient
procedure
preparation
Prior art date
Application number
SE7200662A
Other languages
English (en)
Swedish (sv)
Inventor
G H Phillipps
P J May
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of SE383522B publication Critical patent/SE383522B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
SE7200662A 1971-01-20 1972-01-20 Forfarande for framstellning av anti-inflammatoriskt verksamma 17-karboxylat av steroider tillhorande androstan-serien. SE383522B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB278771A GB1384372A (en) 1971-01-20 1971-01-20 Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids

Publications (1)

Publication Number Publication Date
SE383522B true SE383522B (sv) 1976-03-15

Family

ID=9745890

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7200662A SE383522B (sv) 1971-01-20 1972-01-20 Forfarande for framstellning av anti-inflammatoriskt verksamma 17-karboxylat av steroider tillhorande androstan-serien.

Country Status (17)

Country Link
JP (1) JPS5611720B1 (nl)
AU (1) AU473868B2 (nl)
BE (1) BE778285A (nl)
CA (1) CA1003820A (nl)
CH (1) CH602786A5 (nl)
DE (1) DE2202691A1 (nl)
DK (1) DK132894C (nl)
ES (1) ES399057A1 (nl)
FR (1) FR2122539B1 (nl)
GB (1) GB1384372A (nl)
HK (1) HK34278A (nl)
IE (1) IE36000B1 (nl)
IL (1) IL38589A (nl)
NL (1) NL172511C (nl)
NO (1) NO137321C (nl)
SE (1) SE383522B (nl)
ZA (1) ZA72401B (nl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
DE2444618C2 (de) * 1974-09-16 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue Pregnan-21-säure-Derivate
DE2365102C2 (de) * 1973-12-21 1982-12-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue Pregnansäure-Derivate
DE2319479C2 (de) * 1973-04-14 1982-10-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
GB1514476A (en) * 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
SE427276B (sv) * 1975-04-03 1983-03-21 Hoffmann La Roche Forfarande for framstellning av d-homosteroider
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
IT1114534B (it) * 1978-02-08 1986-01-27 Glaxo Group Ltd Steroide anti-infiammatorio della serie dell'androstano composizioni che lo contengono e procedimento per produrlo
CA1138857A (en) * 1979-01-24 1983-01-04 Leo Alig D-homosteroids
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
AU7576001A (en) 2000-08-05 2002-02-18 Glaxo Group Ltd 6.alpha., 9.alpha.-difluoro-17.alpha.-`(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
EP1383786B1 (en) 2001-04-30 2008-10-15 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004112800A1 (en) 2003-06-19 2004-12-29 Bodor Nicholas S Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
ATE454154T1 (de) 2003-06-19 2010-01-15 Nicholas S Bodor Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti- entzündungswirkung für topische oder lokale verabreichung
GB0316290D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
DE102010029877A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
DE102010029875A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids

Also Published As

Publication number Publication date
NO137321B (no) 1977-10-31
DK132894C (da) 1976-07-26
IE36000B1 (en) 1976-07-21
DK132894B (da) 1976-02-23
CA1003820A (en) 1977-01-18
ES399057A1 (es) 1974-11-01
IE36000L (en) 1972-07-20
GB1384372A (en) 1975-02-19
HK34278A (en) 1978-07-07
AU3811072A (en) 1973-07-26
AU473868B2 (en) 1976-07-08
IL38589A (en) 1976-06-30
FR2122539A1 (nl) 1972-09-01
CH602786A5 (nl) 1978-08-15
NO137321C (no) 1978-02-08
NL7200818A (nl) 1972-07-24
BE778285A (fr) 1972-07-20
NL172511C (nl) 1983-09-16
NL172511B (nl) 1983-04-18
IL38589A0 (en) 1972-03-28
FR2122539B1 (nl) 1975-11-28
DE2202691A1 (de) 1972-08-03
ZA72401B (en) 1973-09-26
JPS5611720B1 (nl) 1981-03-16

Similar Documents

Publication Publication Date Title
SE383522B (sv) Forfarande for framstellning av anti-inflammatoriskt verksamma 17-karboxylat av steroider tillhorande androstan-serien.
SE396079B (sv) Forfarande for framstellning av nya anti-inflammatoriska steroider tillhorande androstan-serien
SE392269B (sv) Forfarande for framstellning av vissa indanyloxitetrazoler
SE398229B (sv) Forfarande for framstellning av 4-fenoxi-fenoxialkankarbonsyraderivat
SE7409801L (sv) Forfarande for framstellning av kinolinforeningar.
SE411904B (sv) Forfarande for framstellning av steroidderivat tillhorande androstan-serien
SE400292B (sv) Forfarande for framstellning av benshydryl-3-karbamoyloximetyl-7-tienylacetamido-7-metoxidecefalosporanat
SE402461B (sv) Steroidhaptener till anvendning for framstellning av antigener
SE399701B (sv) Forfarande for framstellning av hydroxyalkyldiamin
SE405976B (sv) Forfarande for framstellning av anti-inflammatoriska steroider tillhorande androstan-serien
SE394436B (sv) Forfarande for framstellning av 7-halogen-linkomyciner
SE417200B (sv) Forfarande for framstellning av 2-nitro-5-imidazolaldehydderivat
SE395897B (sv) Forfarande for framstellning av 7beta-acylamido-3-metyl-cef-3-em-4-karbonsyror
SE385011B (sv) Forfarande for framstellning av alfa-linkosaminider
SE405478B (sv) Forfarande for framstellning av alfa-sulfoacylcefalosporiner
SE397090B (sv) Forfarande for framstellning av hydroxipyrimidiner
SE408418B (sv) Forfarande for framstellning av 5-fluor-pyrimidiner
SE380795B (sv) Forfarande for framstellning av tiokarbamider
SE380520B (sv) Forfarande for framstellning av 1-cinnamylidenamino-3-bensylidenaminoguanidin
SE382046B (sv) Forfarande for framstellning av 1-aryloxi-2-propanol
SE389333B (sv) Forfarande for framstellning av ackalipolyfosfatkomplex av x-6-desoxi-5-hydroxitetsacyklin.
SE392902B (sv) Forfarande for framstellning av fenylimidazolidinoner
SE386897B (sv) Forfarande for framstellning av n-acyl-(piperazinoetyl)-pyrazoler
SE392724B (sv) Forfarande for framstellning av 7-aminocefalosporansyra
SE407061B (sv) Forfarande for framstellning av bensylpyrimidiner